Cargando…

Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes

BACKGROUND AND OBJECTIVES: The therapeutic effects of the dopamine D2 receptor (D2R) agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous system actions. However, peripheral dopamine directly modulates glucose uptake in insulin-sensitive tissues and lipid metaboli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tavares, G., Marques, D., Barra, C., Rosendo-Silva, D., Costa, A., Rodrigues, T., Gasparini, P., Melo, B.F., Sacramento, J.F., Seiça, R., Conde, S.V., Matafome, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164040/ https://www.ncbi.nlm.nih.gov/pubmed/33933677 http://dx.doi.org/10.1016/j.molmet.2021.101241

Ejemplares similares

Circulating Dopamine Is Regulated by Dietary Glucose and Controls Glucagon-like 1 Peptide Action in White Adipose Tissue
por: Tavares, Gabriela, et al.
Publicado: (2023)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
por: Clausen, Marianne F., et al.
Publicado: (2021)

Dopaminergic Challenge With Bromocriptine in Patients With Severe Brain Injury
por: Celik, JB, et al.
Publicado: (2015)

The Dopamine Agonist Bromocriptine Differentially Affects Fronto-Striatal Functional Connectivity During Working Memory
por: Wallace, Deanna L., et al.
Publicado: (2011)

Enhancement of dopaminergic agonist bromocriptine of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.
por: Iishi, H., et al.
Publicado: (1992)

Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine
por: Aslanoglou, Despoina, et al.
Publicado: (2022)

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
por: Missale, C., et al.
Publicado: (1995)

Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia
por: Liberante, Fabio Giuseppe, et al.
Publicado: (2015)

Peripheral Dopamine Directly Acts on Insulin-Sensitive Tissues to Regulate Insulin Signaling and Metabolic Function
por: Tavares, Gabriela, et al.
Publicado: (2021)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Central Hyperthermia Treated with Bromocriptine
por: Natteru, P., et al.
Publicado: (2017)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Via, Michael A, et al.
Publicado: (2010)

Irisin and Myonectin Regulation in the Insulin Resistant Muscle: Implications to Adipose Tissue: Muscle Crosstalk
por: Gamas, Luis, et al.
Publicado: (2015)

Prediction of response to bromocriptine in acromegaly.
por: Atkinson, A. B., et al.
Publicado: (1978)

Repurposing of Bromocriptine for Cancer Therapy
por: Seo, Ean-Jeong, et al.
Publicado: (2018)

Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis
por: Mendoza-Torreblanca, Julieta Griselda, et al.
Publicado: (2023)

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012)

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015)

Management of pituitary tumour apoplexy with bromocriptine in pregnancy
por: Janssen, Nina M, et al.
Publicado: (2012)

Bromocriptine and insulin sensitivity in lean and obese subjects
por: Bahler, L, et al.
Publicado: (2016)

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
por: Ramteke, Karuna Balwant, et al.
Publicado: (2011)

Agonist and Antagonist Effects of Aripiprazole on D(2)-Like Receptors Controlling Rat Brain Dopamine Synthesis Depend on the Dopaminergic Tone
por: Ma, Guo Fen, et al.
Publicado: (2015)

A(2) Adenosine Receptors Mediate Whole-Body Insulin Sensitivity in a Prediabetes Animal Model: Primary Effects on Skeletal Muscle
por: Sacramento, Joana F., et al.
Publicado: (2020)

Bromocriptine, a clinical and pharmacological review /
por: Thorner, Michael O.
Publicado: (1980)

Distinct Impact of Natural Sugars from Fruit Juices and Added Sugars on Caloric Intake, Body Weight, Glycaemia, Oxidative Stress and Glycation in Diabetic Rats
por: Monteiro-Alfredo, Tamaeh, et al.
Publicado: (2021)

Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes
por: Mahajan, Rajiv
Publicado: (2009)

Evaluating the Impact of Different Hypercaloric Diets on Weight Gain, Insulin Resistance, Glucose Intolerance, and its Comorbidities in Rats
por: Melo, Bernardete F., et al.
Publicado: (2019)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Effect of parasitic infection on dopamine biosynthesis in dopaminergic cells
por: Martin, H.L., et al.
Publicado: (2015)

Bromocriptine Does Not Alter Speed–Accuracy Tradeoff
por: Winkel, Jasper, et al.
Publicado: (2012)

Repositioning of bromocriptine for treatment of acute myeloid leukemia
por: Lara-Castillo, María Carmen, et al.
Publicado: (2016)

Effects of tolcapone and bromocriptine on cognitive stability and flexibility
por: Cameron, Ian G. M., et al.
Publicado: (2018)

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
por: Simon, Rebecca, et al.
Publicado: (2018)

Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects
por: Cincotta, Anthony H.
Publicado: (2023)

Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells
por: Huang, Jinxiang, et al.
Publicado: (2017)

Reduction of Methylglyoxal-Induced Glycation by Pyridoxamine Improves Adipose Tissue Microvascular Lesions
por: Rodrigues, Tiago, et al.
Publicado: (2013)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Photoactivatable Dopamine and Sulpiride to Explore the Function of Dopaminergic Neurons and Circuits
por: Asad, Naeem, et al.
Publicado: (2020)

Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma
por: Menon, Lakshmi P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_de1holkiskc104cvmsbu0j9tcf